Compass Therapeutics (CMPX) Accumulated Depreciation (2019 - 2026)

Compass Therapeutics has reported Accumulated Depreciation for 8 years, with the latest figure at $6.7 million in Q1 2026.

• Quarterly Accumulated Depreciation changed 0.23% year-over-year to $6.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.7 million (changed 0.23% YoY) and the FY2025 annual result came in at $6.6 million, up 4.34% from the prior year.
• Accumulated Depreciation was little changed at $6.7 million in Q1 2026 per CMPX's latest filing, from $6.6 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $6.7 million in Q3 2024 and troughed at $5.2 million in Q2 2022.
• A 5-year average of $6.2 million and a median of $6.4 million in 2024 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2023 and 2025: Accumulated Depreciation rose 14.91% in 2023, then fell 1.43% in 2025.
• Over 5 years, Accumulated Depreciation stood at $5.6 million in 2022, then grew by 12.55% to $6.3 million in 2023, then rose by 1.5% to $6.4 million in 2024, then gained by 4.34% to $6.6 million in 2025, then gained by 0.23% to $6.7 million in 2026.
• According to Business Quant data, Accumulated Depreciation over the past three periods registered $6.7 million, $6.6 million, and $6.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.